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Abstract
Background: Different techniques of liver parenchymal transection have been described, including
the finger fracture, sharp dissection, clamp–crush methods and, more recently, the Cavitron ultrasonic
surgical aspirator (CUSA), the hydrojet and the radiofrequency dissection sealer (RFDS). This review
assesses the benefits and risks associated with the various techniques.
Methods: Randomized clinical trials were identified from the Cochrane Library Trials Register, MEDLINE,
EMBASE, Science Citation Index Expanded and reference lists. Odds ratio (ORs), mean difference (MDs)
and standardized mean differences (SMDs) were calculated with 95% confidence intervals based on
intention-to-treat analysis or available-case analysis.
Results: We identified seven trials including a total of 556 patients. Blood transfusion requirements were
lower with the clamp–crush technique than with the CUSA or hydrojet. The clamp–crush technique was
quicker than the CUSA, hydrojet or RFDS. Infective complications and transection blood loss were greater
with the RFDS than with the clamp–crush method. There was no significant difference between tech-
niques in mortality, morbidity, liver dysfunction or intensive therapy unit and hospital stay.
Conclusions: The clamp–crush technique is more rapid and is associated with lower rates of blood loss
and otherwise similar outcomes when compared with other methods of parenchymal transection. It
represents the reference standard against which new methods may be compared.
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Background
Blood loss is one of the most important factors affecting the
perioperative outcome of patients undergoing liver resection
surgery.1–3 Various techniques have been used to reduce blood loss,
including lowering the central venous pressure,4 hypoventilation5
or vascular occlusion.6,7 Various methods of liver parenchymal
transection have been suggested to decrease blood loss. These
include the finger fracture technique,8 sharp dissection,9,10 Kelly’s
technique11–14 (the clamp–crush technique), ultrasonic dissection
(using the Cavitron ultrasonic surgical aspirator [CUSA]),12,13,15–17
the hydrojet13,15,17 and the radiofrequency dissecting sealer
(RFDS).11,13,14 Among these, the finger fracture technique, clamp–
crush technique and sharp dissection do not require any special
instruments.
The finger fracture technique and the clamp–crush technique
are generally considered to represent the standard forms of liver
parenchymal transection. The ultrasonic dissector (CUSA),
hydrojet and RFDS are newer techniques. Randomized controlled
trials have been published to assess the benefits and risks of
various techniques. We were unable to identify any systematic
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reviews or meta-analyses of parenchymal transection techniques
in liver resection that might provide an evidence base for the
optimal technique for liver parenchymal transection during elec-
tive liver resection surgery.
Materials and methods
Identification of trials and data extraction
Randomized clinical trials comparing one method of parenchy-
mal transection with another were reviewed, irrespective of lan-
guage or publication status. Trials were included irrespective of
the nature of the underlying liver, use of vascular occlusion or the
method of management of the raw surface. Co-interventions
(including radiofrequency [RF] ablation) were allowed, provided
that they were used equally in the intervention groups. Quasi-
randomized studies, in which the methods of allocating partici-
pants to a treatment were not strictly random, cohort studies and
case-control studies were excluded. The Cochrane Hepato-Biliary
Group Controlled Trials Register,18 the Cochrane Central Register
of Controlled Trials (CENTRAL) in the Cochrane Library,
MEDLINE, EMBASE and the Science Citation Index Expanded19
were searched until March 2008 using the MeSH terms: liver
or hepatic or segmentectomy or resection or transection or
hepatectomy and blood loss or blood losses or hemorrhage or
hemorrhages or haemorrhage or haemorrhages or hemostasis
or hemostases or haemostasis or haemostases. A filter recom-
mended by the Cochrane Collaboration20 was used to exclude
non-randomized studies in MEDLINE and EMBASE. The refer-
ences of the identified trials were searched to identify further
relevant trials. Two reviewers independently identified the trials
for inclusion and extracted the following data: year and language
of publication; country of study; year of study; inclusion and
exclusion criteria; sample size; population characteristics, such as
age, gender ratio, major or minor liver resections, normal or cir-
rhotic livers; method of vascular occlusion; management of the
cut surface; outcomes, and methodological quality. Sample size
calculations and intention-to-treat analysis are reported by the
trial authors.
Outcomes
Data for the following outcomes were extracted: mortality at 30
days; mortality at maximal follow-up; perioperative morbidity
(such as re-operations for bleeding, bile leakage, etc.); adverse
events; clinically significant air embolism; biochemical markers of
liver damage (aspartate aminotransferase [AST], alanine ami-
notransferase [ALT]) and markers of liver function (bilirubin,
prothrombin time); blood loss during resection; total operative
blood loss; blood transfusion (number of units, number of
patients requiring blood transfusion); parenchymal transection
time/speed; total operation time; length of hospital stay, and costs
as reported by the authors.
Assessment of methodological quality
Instructions given in the Cochrane Handbook for Systematic
Reviews of Intervention20 and the Cochrane Hepato-Biliary Group
Module18 were followed. Because there is a risk that intervention
effects in randomized trials with inadequate methodological
quality will be overestimated,21–24 the following methodological
quality components were assessed: generation of allocation
sequence; allocation concealment; blinding; incomplete data
outcomes; selective outcome reporting; baseline imbalance; early
stopping; academic bias, and sponsor bias. If the information was
not available in the published report of the trial, the authors were
contacted in order that the trial could be assessed correctly.
Statistical methods
Meta-analyses were carried out according to the recommenda-
tions of the Cochrane Collaboration20 using the software package
RevMan 525 provided by the Cochrane Collaboration. For
dichotomous outcomes, the odds ratio (OR) was calculated with
95% confidence intervals (CIs). For continuous outcomes, mean
differences (MDs) or standardized mean differences (SMDs) were
calculated with 95% CIs. The random-effects model and a fixed-
effect model were used.26,27 In cases of discrepancy between the
two models, we report both results; otherwise we report only the
results from the fixed-effect model. Heterogeneity was explored by
chi-squared test with significance set at a P-value of 0.10, and the
quantity of heterogeneity was measured by I2.28 An I2 of >30%
was considered to indicate statistically significant heterogeneity.
An intention-to-treat analysis29 was performed whenever possible.
Otherwise, an available-case analysis was adopted. Subgroup
analyses for normal livers and chronic liver disease, liver resections
vs. living donor retrievals, minor and major liver resections, dif-
ferent techniques of vascular occlusion and different techniques of
management of the cut surface, and trials with low and high risks
of bias were not performed because of the few trials included
under each outcome.
Results
Description of studies
We identified a total of 887 references through the electronic
searches of the Cochrane Hepato-Biliary Group Controlled Trials
Register and the Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library (n = 107), MEDLINE (n =
393), EMBASE (n = 242), and the Science Citation Index
Expanded (n = 145). Of these, 288 duplicates and 591 clearly
irrelevant references were excluded by reading the abstracts
(Fig. 1). Eight references were retrieved for further assessment. No
references were identified through scanning reference lists of
the identified randomized trials. One reference was excluded17
because randomization had been stopped because of a technical
difficulty. The remaining seven references represented completed
randomized trials which fulfilled the inclusion criteria.10–16 Impor-
tant details of the trials are shown in Table 1. All seven trials
carried a high risk of bias as all lacked blinding of patients and
outcome assessors. Figure 2 shows a methodological quality
summary based on our judgements of the methodological quality
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of the studies. The techniques compared, numbers of participants,
percentages of major resection and use of vascular occlusion are
given in Table 1.
Outcome measures
The primary outcome measures reported by all trials were perio-
perative mortality,10,11,13,14,16 surgery-related complications,10,11,13–16
air embolism,12 blood loss,11–16 number of patients trans-
fused,10,11,13,14 amount of blood transfused,11–13,15 operating
time,10,12,14 transection time,11–13,15,16 transection speed,11,13,14,16
markers of liver parenchymal injury,11,13 markers of liver dysfunc-
tion,13 intensive therapy unit (ITU) stay10,13 and hospital
stay.10,11,13,14 The other outcome measures reported by the trials
were air embolisms detected in the heart,12 costs13 and tumour
exposure at the resection margin.16
References excluded as  
duplicate, n = 288
References excluded as  
irrelevant, n = 591
Randomized controlled trials, 
n = 8 
References identified through electronic searches of 
databases, n = 887 
Randomized controlled trials, 
n = 7 
References excluded after
contacting the authors, n = 1 
(randomization was stopped 
because of technical
difficulties)  
Figure 1 Flow chart of articles identified, included and excluded
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Figure 2 Methodological quality summary: review authors' judge-
ments of each study on each methodological quality item
Table 1 Characteristics of included studies
Study (year) Techniques compared and
number of patients in
each group
Major resection Cirrhosis Vascular occlusion
Rau et al. (2001)15 Hydrojet (n = 31)
CUSA (n = 30)
24 (39.3%) None Intermittent
Takayama et al. (2001)16 CUSA (n = 66)
Clamp–crush (n = 66)
43 (32.6%) None Intermittent
Arita et al. (2005)11 RFDS (n = 40)
Clamp–crush (n = 40)
20 (25%) 21 (26.3%) Intermittent
Koo et al. (2005)12 CUSA (n = 25)
Clamp–crush (n = 25)
Not stated None No
Smyrniotis et al. (2005)10 Sharp transection (n = 41)
Clamp–crush (n = 41)
60 (73%) 12 (14.6%) Selective intermittent but
equal in each group
Lesurtel et al. (2005)13 CUSA (n = 25)
Hydrojet (n = 25)
RFDS (n = 25)
Clamp–crush (n = 25)
61 (61%) None Only in clamp–crush
Lupo et al. (2007)14 RFDS (n = 40)
Clamp–crush (n = 40)
21 (42%) 7 (14%) No
CUSA, Cavitron ultrasonic surgical aspirator; RFDS, radiofrequency dissection sealer
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CUSA vs. the clamp–crush technique
In the three trials that compared outcomes between the CUSA and
clamp–crush methods,12,13,16 a total of 232 patients were random-
ized to either CUSA (116 patients) or clamp–crush (116 patients).
One trial13 compared CUSA without vascular occlusion and the
clamp–crush technique with vascular occlusion and was thus con-
sidered to differ from the other two.12,16 This trial was analysed
separately.
Trials comparing the CUSA and clamp–crush techniques
with vascular occlusion
There was no statistically significant difference between the tech-
niques in mortality, morbidity, operative blood loss, median
transection blood loss, amount of blood transfused, operating
time or transection time. The number of patients with air embo-
lism detected in the heart by echocardiography was significantly
higher in the CUSA group (OR 24.77, 95% CI 1.34–457.61).
However, none of the patients had clinically significant air
embolism.
Trial of CUSA without vascular occlusion and the
clamp–crush technique with vascular occlusion
Significantly more blood was lost (MD 2.50 ml/cm2, 95% CI 1.01–
3.99) and significantly more patients required blood transfusion
(OR 11.29, 95% CI 1.29–98.89) with CUSA without vascular
occlusion than with the clamp–crush technique with vascular
occlusion. Transection speed was also significantly quicker (MD
-1.60, 95% CI -2.31 to -0.89) in the clamp–crush method than in
CUSA. There was no statistically significant difference between
the two groups in mortality and morbidity, peak AST, ALT or
bilirubin level, prothrombin activity, ITU or hospital stay between
the two groups. The CUSA was between three and six times more
costly than the clamp–crush technique, depending upon the
number of cases performed per year, because of transection speed,
blood loss and the cost of maintaining the instrument.13
RFDS vs. the clamp–crush technique
In the three trials that compared outcomes between the RFDS and
clamp–crush methods,11,13,14 180 patients were randomized to
either the RFDS (89 patients) or clamp–crush (91 patients) tech-
niques. There was no mortality in either group. Infected intra-
abdominal collections were significantly higher in the RFDS
group than in the clamp–crush group (OR 11.02, 95% CI 1.38–
88.28). The difference between the techniques in the incidence of
wound infection approached statistical significance in favour of
the clamp–crush technique (OR 7.58, 95% CI 0.80–68.46).
Transection blood loss was higher in the RFDS group than in the
clamp–crush group (MD 1.90 ml/cm2, 95% CI 0.92–2.88). There
was no difference between the two groups in the number of people
requiring a blood transfusion (OR 1.19, 95% CI 0.50–2.82). The
amount of blood transfused could not be estimated as no-one in
the clamp–crush group underwent blood transfusion in the only
trial11 that reported on this outcome. By imputing values of 0.01
and 0.01 for mean and standard deviation (SD), instead of 0 and
0, we were able to calculate a mean difference.30 This was statisti-
cally significantly lower in the clamp–crush method (number of
units: MD 1.49, 95% CI 1.27–1.71; amount of blood transfused:
MD 359.99 ml, 95% CI 307.31–412.67).
There was no statistically significant difference in AST, ALT or
bilirubin levels, prothrombin activity, or ITU or hospital stay.
Transection speed was statistically significantly quicker (MD
1.40 cm2/min, 95% CI 0.57–2.23) in the clamp–crush method
than in RFDS in the only trial that reported on this outcome.13
There was no difference in median operating time between the
two groups in the one trial that reported this.14 Costs were calcu-
lated in one trial13 based on transection speed, blood loss and the
cost of maintaining the instrument. The RFDS was approximately
three times more costly than the clamp–crush technique.
On exclusion of the trial, which used vascular occlusion in the
clamp–crush group alone,13 infected intra-abdominal collections
favouring the clamp–crush technique and the amount of blood
transfused (after imputing the mean and SD as mentioned pre-
viously) were the only outcomes for which the groups showed
statistically significant differences. This was because transection
speed and costs were reported only in the trial that was excluded
in the sensitivity analysis.13
Hydrojet vs. the clamp–crush technique
Only one trial provided comparison between the clamp–crush
and hydrojet techniques.13 The hydrojet group experienced greater
blood loss (MD 2.00 ml/cm2, 95% CI 0.86–3.14) and a greater
need for blood transfusion (OR 11.29, 95% CI 1.29–98.89). The
clamp–crush method was statistically significantly quicker (MD
1.50 cm2/min, 95% CI 2.33 - 0.67). There were no statistically
significant differences in mortality (OR 5.43, 95% CI 0.25–
118.96), morbidity, peak AST or ALT, bilirubin level, prothrombin
activity, median ITU stay (1 day in both groups) or hospital stay (9
days in both groups). The hydrojet method was approximately
two to four times more costly than the clamp–crush technique
depending upon the number of cases operated per year based on
transection speed, blood loss and the cost of maintaining the
instrument.
Sharp dissection vs. the clamp–crush technique
Only one trial compared outcomes between the sharp dissection
and clamp–crush techniques.10 There was no statistically signifi-
cant difference in median intraoperative blood loss (500 ml in
sharp dissection vs. 460 ml in clamp–crush) or the number of
people requiring blood transfusion (OR 0.80, 95% CI 0.32–2.01).
Neither was there any statistically significant difference between
the two groups in operative morbidity or mortality, median oper-
ating time (205 min in sharp dissection vs. 211 min in clamp–
crush), median ITU stay (1 day in both groups) or hospital stay
(10 days in sharp dissection vs. 11 days in clamp–crush).
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Hydrojet vs. CUSA
Two trials compared outcomes between the hydrojet and CUSA
techniques.13,15 There was no statistically significant difference
between the two groups in transection blood loss, intraoperative
blood loss, number of people requiring transfusion or mean
transfusion requirements, mortality (OR 1.00, 95% CI 0.13–7.72),
morbidity, peak AST or ALT, bilirubin levels, prothrombin activ-
ity, transection time or speed, median ITU stay or median hospital
stay. Costs were calculated in one study13 based on transection
speed, blood loss and the cost of maintaining the instrument. The
hydrojet was approximately a third more cost-effective than
CUSA.
RFDS vs. CUSA techniques
Only one trial compared outcomes between the RFDS and CUSA
methods.13 There was no statistically significant difference in
transection blood loss, the number of people requiring blood
transfusion, mortality (OR 5.43, 95% CI 0.25–118.96), morbidity,
peak AST or ALT, bilirubin levels, prothrombin activity, transec-
tion speed, median ITU stay (1 day in both groups) or median
hospital stay (9 days in both groups). Costs were calculated
according to transection speed, blood loss and the cost of main-
taining the instrument. Depending upon the number of cases
operated, RFDS costs were approximately 50–100% of those of
CUSA.
RFDS vs. the hydrojet
Only one trial compared outcomes between the RFDS and hydro-
jet methods.13 There was no statistically significant difference in
transection blood loss, number of people requiring blood trans-
fusion, mortality (OR 0.18, 95% CI 0.01–4.04), morbidity, peak
AST or ALT, bilirubin level, prothrombin activity, transection
speed, median ITU stay (1 day in both groups) or median hospital
stay (9 days in both groups). Costs were calculated based on
transection speed, blood loss and the cost of maintaining the
instrument. The RFDS technique cost about 25% more than the
hydrojet.
Discussion
In this systematic review, no differences were found in mortality
rates in liver resection surgery irrespective of the method used for
parenchymal transection. However, the mortality associated with
liver resection surgery is low31 and the trials were not adequately
powered to identify significant differences in mortality. This
review also found no significant differences between the various
techniques in morbidity, apart from in one trial, which showed
RFDS to be more strongly associated with infective complications
than the clamp–crush method. The reason for this difference was
not clear, but the increased amount of non-viable tissue and the
consequent necrosis of biliary ducts left at the resection margin
may influence the rate of abscesses in RFDS.14 No differences
between the techniques were noted in markers of liver injury or
length of ITU or hospital stay.
Given the similarities between the techniques in terms of mor-
bidity and mortality rates, we must establish the optimal transec-
tion technique according to other considerations. Blood and
blood products are expensive and, in larger studies, blood loss in
liver surgery has been shown to correlate with both morbidity and
mortality.1–3 The clamp–crush technique resulted in the lowest
blood loss and transfusion requirements. However, in the trial that
compared clamp–crush outcomes with those of three other tech-
niques (CUSA, RFDS and the hydrojet),13 continuous portal triad
clamping was used in the clamp–crush technique, but no inflow
occlusion was used in the other techniques. Another trial12 com-
paring outcomes between the clamp–crush technique and CUSA
did not employ vascular occlusion. This trial did not find any
difference in blood transfusion requirements between the two
groups. The third trial16 that compared the clamp–crush tech-
nique with CUSA employed intermittent vascular occlusion in
both groups. This trial did not report on blood transfusion
requirements, but did report that the median transection blood
loss was similar in the two groups. Thus, it is likely that vascular
occlusion played an important role in decreasing blood transfu-
sion requirements in the clamp–crush technique in the trials in
which vascular occlusion was used in the clamp–crush technique
only. This may have produced a bias in favour of the clamp–crush
technique in terms of blood loss and transfusion and thus the
technique should be assessed as a package. The role of vascular
occlusion in liver surgery and the optimal method is controversial.
In a recent review,32 intermittent vascular occlusion was shown to
be safe and to decrease blood loss and blood transfusion require-
ments, but it did not affect morbidity. Data on other factors influ-
encing blood loss during liver surgery, including the use of low
central venous pressure, hypoventilation and drugs such as tran-
examic acid, were not reported in most of the trials.
In the comparison of transection methods, transection speed is
more important than operating time as this takes the resection
surface area into account, which may influence both transection
duration and blood loss. The clamp–crush technique is quicker
than the CUSA, hydrojet or RFDS methods. Transection speeds in
sharp dissection and the clamp–crush technique have not been
compared, but no difference was found in operating time. On a
practical level, the accuracy of the implication that the use of the
faster technique could facilitate increased theatre usage, thereby
allowing additional procedures to be performed on the same day
and thus reducing both operating costs and waiting times for
surgery, remains to be resolved.
Air embolism can be a fatal complication of liver surgery. Koo
et al.12 detected a significantly higher number of air emboli in the
heart in their CUSA group than in their clamp–crush group. All
large emboli (half or more of the right heart diameter) were found
in the CUSA group.12 However, none of the patients in either
group developed clinical symptoms. The importance of this
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finding in the absence of clinical symptoms is not clear, but it is
likely to reflect the risk of a massive air embolism with CUSA.
Liver surgery is expensive in terms of personnel, facilities and
equipment. The clamp–crush and sharp dissection techniques
do not involve any additional instruments. A cost comparison
between the clamp–crush technique and other techniques
revealed that clamp–crush is two to six times cheaper than other
methods, depending on the number of surgeries performed each
year.13 Furthermore, the clamp–crush technique may contribute
to cost savings because it decreases blood loss and transfusion
requirements.
This review is restricted by the small number of trials in each
comparison, which makes it impossible to perform subgroup
analyses. Sample size is not sufficiently powered to detect clinically
significant differences in the primary outcomes. All the trials were
at high risk of bias, mainly because of the lack of blinding.
Although patient blinding can be easily achieved, even this was
not reported in the trials and it is not safe to assume that the
patients were blinded to the groups. Blinding of outcome assessors
is more difficult to achieve. Bias resulting from lack of blinding
can be minimized by using objective outcomes whenever feasible13
and by involving a second team of surgeons.
In conclusion, the clamp–crush technique is more rapid and is
associated with lower blood loss than other methods of parenchy-
mal transection; it thus remains the reference standard against
which new methods may be compared. There is an ongoing need
for high-quality, randomized controlled trials, with sufficient
sample sizes and factorial designs, to identify the effects of con-
founding factors, such as the method of vascular occlusion,
quality of parenchyma resected (cirrhotic/post-chemotherapy),
low central venous pressure, hypoventilation and methods of
dealing with the cut surface of liver (e.g. tissue glue).
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